Histology Impacts the Outcome of Peripheral T-Cell Lymphomas after High Dose Chemotherapy and Stem Cell Transplant

Jagasia, Madan; Morgan, David R.; Goodman, Stacey; Hamilton, Katherine; Kinney, Marsha C.; Shyr, Yu; Stein, Richard S.; Zic, John A.; Greer, John P.

doi:10.1080/10428190412331272749

Cited by 65 publications

(40 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many studies, the success rate following ASCT varies with the pre-transplant IPI and by histological subtype, with ALCL demonstrating consistently superior salvage rates than PTCL-NOS. 7,8,14,15 Although IPI did not affect outcome in our study, we were able to confirm the favourable impact of ALCL subtype. It has been suggested that such favourable results in ALCL may not necessarily extend to ALK negative ALCL -as one small study has suggested poor outcome with ASCT in this population.…”

Section: Discussionsupporting

confidence: 74%

“…However, the numbers of patients in the various studies are relatively small. [6][7][8] These results are similar to a comparable group of patients with B-cell lymphomas. 7,9 The role of allogeneic stem cell transplantation (Allo-SCT) for the treatment of relapsed lymphoma remains unclear, although it has been demonstrated to be an effective salvage strategy in selected patients.…”

Section: Introductionsupporting

confidence: 77%

“…In the relapsed setting, previous reports have demonstrated that patients with chemotherapy-sensitive disease respond favourably to ASCT, with long-term survival rates of approximately 35-45%. 7,8,10 We demonstrate similar OS (53%) and PFS (50%) in our study, and on multivariate analysis, chemotherapy sensitivity was the only factor to significantly impact upon outcome (Table 3). In many studies, the success rate following ASCT varies with the pre-transplant IPI and by histological subtype, with ALCL demonstrating consistently superior salvage rates than PTCL-NOS.…”

Section: Discussionmentioning

confidence: 51%

“…We demonstrate that in a selected group of patients with PTCL (those undergoing ASCT), the 3-year OS was 53%, which compares favourably with patients undergoing similar treatment programmes for both PTCL and B-cell disease as reported in other, smaller studies. [7][8][9][10] Several small, uncontrolled trials have attempted to evaluate the role of ASCT in PTCL, either in the relapsed setting or as consolidation following conventional-dose primary therapy. In the relapsed setting, previous reports have demonstrated that patients with chemotherapy-sensitive disease respond favourably to ASCT, with long-term survival rates of approximately 35-45%.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

Feyler

Prince

Pearce

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous subset of lymphomas with a poorer prognosis compared with B-cell lymphomas. We conducted a retrospective study of 82 patients who received high-dose therapy for PTCL (autologous SCT (ASCT) N ¼ 64; allogeneic SCT (Allo-SCT) N ¼ 18). With a median follow-up from ASCT of 37 months from transplant, 33 patients were alive; 20 died of progressive disease, 10 died from non-relapse mortality (NRM) with 1 unknown cause. Three-year overall survival (OS) and progression-free survival (PFS) were 53% (95% confidence interval (CI) 42, 67) and 50% (95% CI 39, 64), respectively. Factors significantly affecting OS and PFS on univariate analysis were histological subtype and chemotherapy sensitivity. In a multivariate analysis, the only factor with significant impact was chemotherapy sensitivity. After a median follow-up from Allo-SCT of 57 months, five patients were alive; five died of progressive disease and eight died from NRM. The 3-year OS and PFS were 39% (95% CI 22, 69) and 33% (95% CI 17, 64), respectively, and the 3-year relapse rate was 28% (95% CI 6, 50). These results demonstrate that high-dose chemotherapy with autologous stem cell rescue has a substantial role in the management of T-cell lymphoma. The use of full-intensity allogeneic transplantation is limited by high transplant-related mortality, and exploration of reduced intensity regimens is warranted.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Introductionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 51%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

Feyler

Prince

Pearce

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Briefly, Gene@Work discovers global gene expression signatures that are common to an entire set of at least n experiments (the support set), where n was chosen as n = n0; n0 being the total number of samples in the set. Differentially expressed genes were identified by comparing expected gene expression probability densities, empirically computed from the experimental set with predefined threshold (51), and ranked according to statistical significance (gene z score). The data discussed in this publication have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/ geo/) and are accessible through GEO Series accession number GSE6184.…”

Section: Methodsmentioning

confidence: 99%